Lycia Therapeutics
A biotech company developing first-in-class therapeutics for a wide range of difficult-to-treat diseases, including autoimmune and inflammatory diseases.
Headquartered in South San Francisco, Lycia was established in 2019 within founding investor Versant Ventures’ Inception Therapeutics Discovery Engine in collaboration with academic founder Carolyn Bertozzi, professor of chemistry and HHMI investigator at Stanford University.
Lycia's proprietary lysosomal targeting chimeras (LYTACs) platform enables the development of several therapeutic modalities, including antibodies and small molecules, with the potential to inhibit many targets previously considered intractable across a spectrum of therapeutic areas and diseases.
Latest Lycia Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze